Trial Profile
An Independent Evaluator-Blind, Dose-Escalation, Untreated-Controlled, Within-Subject, Phase 2a Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of BMT 101 Administration for the Prevention of Hypertrophic Scar
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs BMT 101 (Primary)
- Indications Hypertrophic scars
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hugel
- 22 May 2023 Status changed from recruiting to discontinued.
- 14 Apr 2022 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.
- 14 Apr 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.